Company news

Organogenesis Holdings Inc. news in 2026

Organogenesis Holdings Inc.'s news releases, calls and decks from 2026, newest first.

View company

Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results

November 5, 2026

Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers

October 12, 2026

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026

October 12, 2026

Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results

August 6, 2026

Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers

July 27, 2026

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

July 9, 2026

Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis

July 6, 2026

Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results

May 7, 2026

Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®

April 27, 2026

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026

April 5, 2026

Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM

April 5, 2026

Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue

February 26, 2026

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026

February 19, 2026

Calls in 2026